Ben Tran

732 total citations · 1 hit paper
20 papers, 360 citations indexed

About

Ben Tran is a scholar working on Surgery, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ben Tran has authored 20 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Surgery, 6 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ben Tran's work include Bladder and Urothelial Cancer Treatments (14 papers), Urinary and Genital Oncology Studies (8 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Ben Tran is often cited by papers focused on Bladder and Urothelial Cancer Treatments (14 papers), Urinary and Genital Oncology Studies (8 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Ben Tran collaborates with scholars based in Australia, United States and France. Ben Tran's co-authors include C J Palmer, Y L Tsai, Yohann Loriot, Spyros Triantos, Nadine Houédé, Sydney Akapame, Arlene O. Siefker‐Radtke, Ja Hyeon Ku, Se Hoon Park and Nicole L. Stone and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Analytical Chemistry.

In The Last Decade

Ben Tran

16 papers receiving 344 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

2023 132 citations Yohann Loriot, Nobuaki Matsubara et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ben Tran Australia	8	159	130	74	67	51	20	360
Antonio Cuomo Italy	11	196 1.2×	74 0.6×	97 1.3×	39 0.6×	95 1.9×	15	428
Nobuaki Hattori Japan	9	194 1.2×	91 0.7×	68 0.9×	29 0.4×	160 3.1×	12	473
Mia R. Kumar United States	9	154 1.0×	226 1.7×	79 1.1×	166 2.5×	41 0.8×	9	523
Masaki Kuwabara Japan	10	22 0.1×	117 0.9×	119 1.6×	48 0.7×	74 1.5×	23	370
Dubo Chen China	10	50 0.3×	54 0.4×	69 0.9×	72 1.1×	32 0.6×	22	294
Debalina Sarkar India	7	36 0.2×	101 0.8×	90 1.2×	66 1.0×	23 0.5×	12	341
Harumi Saeki Japan	11	49 0.3×	135 1.0×	167 2.3×	32 0.5×	45 0.9×	37	366
Myra Coppage United States	13	121 0.8×	87 0.7×	29 0.4×	89 1.3×	9 0.2×	29	593
Andrea Exeni Argentina	7	108 0.7×	63 0.5×	116 1.6×	36 0.5×	16 0.3×	12	351
Modesto Cruz Japan	11	150 0.9×	69 0.5×	16 0.2×	14 0.2×	112 2.2×	21	436

Countries citing papers authored by Ben Tran

Since Specialization

Citations

This map shows the geographic impact of Ben Tran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Tran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Tran more than expected).

Fields of papers citing papers by Ben Tran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben Tran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Tran. The network helps show where Ben Tran may publish in the future.

Co-authorship network of co-authors of Ben Tran

This figure shows the co-authorship network connecting the top 25 collaborators of Ben Tran. A scholar is included among the top collaborators of Ben Tran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben Tran. Ben Tran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hansen, Aaron R., Alison Yan Zhang, Valentina Boni, et al.. (2025). A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).. Journal of Clinical Oncology. 43(5_suppl).

Daneshmand, Siamak, Renata Zaucha, James W.F. Catto, et al.. (2025). Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. European Urology. 89(2). 165–173.

Udovicich, Cristian, Mathias Bressel, Jamil Manji, et al.. (2025). PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study. Journal of Nuclear Medicine. 66(4). 531–536. 2 indexed citations

Tyson, Mark D., Edward Uchio, Shreyas Joshi, et al.. (2025). FINAL RESULTS: BOND-003 COHORT C- PHASE 3, SINGLE-ARM STUDY OF INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC FOR HIGH-RISK BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU. The Journal of Urology. 213(5S2). 4 indexed citations

Tran, Ben, et al.. (2024). Burden of Kidney Disease in an Aging Population Living with HIV in the United States. AIDS Patient Care and STDs. 38(12). 543–550.

Woon, Dixon, et al.. (2024). Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review. British Journal of Urology. 135(2). 214–221. 1 indexed citations

Lee, Lui Shiong, Eiji Kikuchi, Hiroshi Kitamura, et al.. (2023). Risk stratification and management of non‐muscle‐invasive bladder cancer: A physician survey in six Asia‐Pacific territories. International Journal of Urology. 31(1). 64–71. 1 indexed citations

Weickhardt, Andrew, Farshad Foroudi, Nathan Lawrentschuk, et al.. (2023). Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502). European Urology Oncology. 7(3). 469–477. 11 indexed citations

Loriot, Yohann, Nobuaki Matsubara, Se Hoon Park, et al.. (2023). Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine. 389(21). 1961–1971. 132 indexed citations breakdown →

10.

Gurney, Howard, Timothy Clay, Niara Oliveira, et al.. (2023). Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia. Asia-Pacific Journal of Clinical Oncology. 19(6). 585–595. 3 indexed citations

11.

Catto, James W.F., Ben Tran, Viraj A. Master, et al.. (2023). Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.. Journal of Clinical Oncology. 41(6_suppl). 503–503. 7 indexed citations

12.

Uchio, Edward, Donald L. Lamm, Neal D. Shore, et al.. (2022). A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).. Journal of Clinical Oncology. 40(6_suppl). TPS598–TPS598. 10 indexed citations

13.

Liow, Elizabeth & Ben Tran. (2020). Precision oncology in urothelial cancer. ESMO Open. 5(Suppl 1). e000616–e000616. 9 indexed citations

14.

Steinberg, Gary D., Juergen E. Gschwend, Ben Tran, et al.. (2020). A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.. Journal of Clinical Oncology. 38(6_suppl). TPS603–TPS603. 8 indexed citations

15.

Sridhar, Srikala S., Normand Blais, Ben Tran, et al.. (2020). Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. JAMA Oncology. 6(11). 1751–1751. 25 indexed citations

16.

Nekolla, Katharina, Nicolas Brieu, Moritz Widmaier, et al.. (2019). Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting. Annals of Oncology. 30. v49–v50. 2 indexed citations

17.

Sridhar, Srikala S., Normand Blais, Ben Tran, et al.. (2018). Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).. Journal of Clinical Oncology. 36(15_suppl). 4505–4505. 6 indexed citations

18.

Sridhar, Srikala S., Normand Blais, Scott North, et al.. (2015). A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993).. Journal of Clinical Oncology. 33(15_suppl). TPS4573–TPS4573.

19.

Zhang, Taylor, Jennifer Zhang, Daniel Hewitt, et al.. (2012). Identification and Characterization of Buried Unpaired Cysteines in a Recombinant Monoclonal IgG1 Antibody. Analytical Chemistry. 84(16). 7112–7123. 54 indexed citations

20.

Tsai, Y L, et al.. (1994). Detection of poliovirus, hepatitis A virus, and rotavirus from sewage and ocean water by triplex reverse transcriptase PCR. Applied and Environmental Microbiology. 60(7). 2400–2407. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact